The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced AdvanceGxP, a new service designed to offer earlier practical support to companies developing advanced manufacturing technologies for medicines. This initiative aims to help promising technologies reach patients more quickly.
AdvanceGxP will initially focus on advanced manufacturing technologies, including personalised treatments made near hospitals and clinics, manufacturing in space, and the use of AI, robotics, and automation. The service is being developed to help innovators address regulatory and quality questions at an earlier stage, which could reduce the risk of avoidable redesigns and delays.
Funding for AdvanceGxP has been secured from the Office for Life Sciences (OLS). The MHRA plans to recruit a new specialist team and develop the service, including how organisations will access it and which technologies will be prioritised. Initial capacity will be limited as the approach is developed and tested.